請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69850
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳,賈景山 | |
dc.contributor.author | Yu-Chung Chuang | en |
dc.contributor.author | 莊祐中 | zh_TW |
dc.date.accessioned | 2021-06-17T03:30:48Z | - |
dc.date.available | 2028-02-21 | |
dc.date.copyright | 2018-03-07 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-02-22 | |
dc.identifier.citation | 1. Akins, R. L. and Rybak, M. J. (2001). 'Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.' Antimicrob. Agents Chemother. 45(2): 454-459.
2. Annane, D., Bellissant, E. and Cavaillon, J. M. (2005). 'Septic shock.' Lancet 365(9453): 63-78. 3. Arias, C. A., Contreras, G. A. and Murray, B. E. (2010). 'Management of multidrug-resistant enterococcal infections.' Clin. Microbiol. Infect. 16(6): 555-562. 4. Balli, E. P., Venetis, C. A. and Miyakis, S. (2014). 'Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.' Antimicrob. Agents Chemother. 58(2): 734-739. 5. Baptista, J. P., Udy, A. A., Sousa, E., et al. (2011). 'A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance.' Crit. Care 15(3): R139. 6. Barbour, S., Marion, C., Kennedy, L., et al. (2013). 'Treatment of vancomycin-resistant enterococcal bacteremia in an observational cohort of neutropenic oncology patients daptomycin versus linezolid.' Infectious Diseases in Clinical Practice 21(4): 240-246. 7. Bio, L. L., Perez, M. E., MacDougall, C., et al. (2011). 'Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia.' Infectious Diseases in Clinical Practice 19(5): 343-347. 8. Boucher, H. W., Talbot, G. H., Bradley, J. S., et al. (2009). 'Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.' Clin. Infect. Dis. 48(1): 1-12. 9. Bozdogan, H. (1987). 'Model selection and Akaike's Information Criterion (AIC): The general theory and its analytical extensions.' Psychometrika 52(3): 345-370. 10. Britt, N. S., Potter, E. M., Patel, N., et al. (2015). 'Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.' Clin. Infect. Dis. 61(6): 871-878. 11. Britt, N. S., Potter, E. M., Patel, N., et al. (2017). 'Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.' Clin. Infect. Dis. 64(5): 605-613. 12. Bryan, C. S., Reynolds, K. L. and Brown, J. J. (1985). 'Mortality associated with enterococcal bacteremia.' Surg. Gynecol. Obstet. 160(6): 557-561. 13. Caballero-Granado, F. J., Becerril, B., Cuberos, L., et al. (2001). 'Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia.' Clin. Infect. Dis. 32(4): 587-594. 14. Cai, Y., Chai, D., Falagas, M. E., et al. (2013). 'Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study.' Expert Opin Investig Drugs 22(3): 309-315. 15. Carrol, E. D., Guiver, M., Nkhoma, S., et al. (2007). 'High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease.' Pediatr. Infect. Dis. J. 26(5): 416-422. 16. Casapao, A. M., Kullar, R., Davis, S. L., et al. (2013). 'Multicenter study of high-dose daptomycin for treatment of enterococcal infections.' Antimicrob. Agents Chemother. 57(9): 4190-4196. 17. Cattoir, V. and Leclercq, R. (2013). 'Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?' J. Antimicrob. Chemother. 68(4): 731-742. 18. Chou, C. H., Lee, N. Y., Lee, H. C., et al. (2012). 'Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan.' J. Microbiol. Immunol. Infect. 45(3): 221-227. 19. Chow, J. W. and Yu, V. L. (1999). 'Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.' Int. J. Antimicrob. Agents 11(1): 7-12. 20. Chuang, Y. C., Chang, S. C. and Wang, W. K. (2010). 'High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy.' PLoS One 5(11): e14133. 21. Chuang, Y. C., Chang, S. C. and Wang, W. K. (2012). 'Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia.' Crit. Care Med. 40(8): 2273-2280. 22. Chuang, Y. C., Lin, H. Y., Chen, P. Y., et al. (2016). 'Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose.' Clin. Microbiol. Infect. 22(10): 890 e891-890 e897. 23. Chuang, Y. C., Lin, H. Y., Chen, P. Y., et al. (2017). 'Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.' Clin. Infect. Dis. 64(8): 1026-1034. 24. Chuang, Y. C., Sheng, W. H., Li, S. Y., et al. (2011). 'Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia.' Clin. Infect. Dis. 52(3): 352-360. 25. Chuang, Y. C., Wang, J. T., Lin, H. Y., et al. (2014). 'Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.' BMC Infect. Dis. 14(1): 687. 26. Clinical and Laboratory Standards Institute (2010). Performance standards for antimicrobial susceptibility testing: 20th informational supplement, M100-S20. Wayne, PA., CLSI. 27. Cockcroft, D. W. and Gault, M. H. (1976). 'Prediction of Creatinine Clearance from Serum Creatinine.' Nephron 16(1): 31-41. 28. Crank, C. W., Scheetz, M. H., Brielmaier, B., et al. (2010). 'Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.' Clin. Ther. 32(10): 1713-1719. 29. DiazGranados, C. A., Zimmer, S. M., Klein, M., et al. (2005). 'Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis.' Clin. Infect. Dis. 41(3): 327-333. 30. Domingo, M. C., Huletsky, A., Giroux, R., et al. (2005). 'High prevalence of glycopeptide resistance genes vanB, vanD, and vanG not associated with enterococci in human fecal flora.' Antimicrob. Agents Chemother. 49(11): 4784-4786. 31. Dubrovskaya, Y., Kubin, C. J. and Furuya, E. Y. (2008). Daptomycin (D) compared to linezolid (L) for primary treatment of vancomycin-resistant enterococcal bacteremia (VREB). 46th Annu. Meet. Infect. Dis. Soc. Am. 32. Dvorchik, B. H., Brazier, D., DeBruin, M. F., et al. (2003). 'Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.' Antimicrob. Agents Chemother. 47(4): 1318-1323. 33. Dvorchik, B. H. and Damphousse, D. (2005). 'The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.' J. Clin. Pharmacol. 45(1): 48-56. 34. El-Lababidi, R. M., Topal, J. and Tsukerman, M. (2007). Daptomycin and linezolid in the treatment of vancomycin-resistant enterococcal bacteremia: a retrospective analysis of treatment outcomes. 45th Annu. Meet. Infect. Dis. Soc. Am. 35. Enoch, D. A., Bygott, J. M., Daly, M. L., et al. (2007). 'Daptomycin.' J. Infect. 55(3): 205-213. 36. Erlandson, K. M., Sun, J., Iwen, P. C., et al. (2008). 'Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.' Clin. Infect. Dis. 46(1): 30-36. 37. Espy, M. J., Uhl, J. R., Sloan, L. M., et al. (2006). 'Real-time PCR in clinical microbiology: applications for routine laboratory testing.' Clin. Microbiol. Rev. 19(1): 165-256. 38. Figueroa, D. A., Mangini, E., Amodio-Groton, M., et al. (2009). 'Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.' Clin. Infect. Dis. 49(2): 177-180. 39. Furuya, E. Y., Kubin, C., Yin, M., et al. (2005). Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia. 45th Intersci. Conf. Antimicrob. Agents Chemother. 40. Gallagher, J. C., Perez, M. E., Marino, E. A., et al. (2009). 'Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.' Pharmacotherapy 29(7): 792-799. 41. Gerson, S. L., Kaplan, S. L., Bruss, J. B., et al. (2002). 'Hematologic effects of linezolid: summary of clinical experience.' Antimicrob. Agents Chemother. 46(8): 2723-2726. 42. Hackett, S. J., Guiver, M., Marsh, J., et al. (2002). 'Meningococcal bacterial DNA load at presentation correlates with disease severity.' Arch. Dis. Child. 86(1): 44-46. 43. Hall, A. D., Steed, M. E., Arias, C. A., et al. (2012). 'Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.' Antimicrob. Agents Chemother. 56(6): 3174-3180. 44. Hall Snyder, A., Werth, B. J., Barber, K. E., et al. (2014). 'Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.' J. Antimicrob. Chemother. 69(8): 2148-2154. 45. Harbour, R. and Miller, J. (2001). 'A new system for grading recommendations in evidence based guidelines.' BMJ 323(7308): 334-336. 46. Hastie, T. and Tibshirani, R. (1995). 'Generalized additive models for medical research.' Stat. Methods Med. Res. 4(3): 187-196. 47. Hindler, J. A., Wong-Beringer, A., Charlton, C. L., et al. (2015). 'In vitro activity of daptomycin in combination with beta-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.' Antimicrob. Agents Chemother. 59(7): 4279-4288. 48. Ho, Y. C., Chang, S. C., Lin, S. R., et al. (2009). 'High levels of mecA DNA detected by a quantitative real-time PCR assay are associated with mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia.' J. Clin. Microbiol. 47(5): 1443-1451. 49. Humphries, R. M., Pollett, S. and Sakoulas, G. (2013). 'A current perspective on daptomycin for the clinical microbiologist.' Clin. Microbiol. Rev. 26(4): 759-780. 50. Jindai, K., Strerath, M. S., Hess, T., et al. (2014). 'Is a single positive blood culture for Enterococcus species representative of infection or contamination?' Eur. J. Clin. Microbiol. Infect. Dis. 33(11): 1995-2003. 51. Kraft, S., Mackler, E., Schlickman, P., et al. (2011). 'Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients.' Support. Care Cancer 19(12): 1969-1974. 52. Kullar, R., Davis, S. L., Levine, D. P., et al. (2011). 'High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.' Pharmacotherapy 31(6): 527-536. 53. Kumar, A., Roberts, D., Wood, K. E., et al. (2006). 'Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.' Crit. Care Med. 34(6): 1589-1596. 54. Kuo, A. J., Su, L. H., Shu, J. C., et al. (2014). 'National surveillance on vancomycin-resistant Enterococcus faecium in Taiwan: emergence and widespread of ST414 and a Tn1546-like element with simultaneous insertion of IS1251-like and IS1678.' PLoS One 9(12): e115555. 55. Kvirikadze, N., Suseno, M., Vescio, T., et al. (2006). 'Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia.' Scand. J. Infect. Dis. 38(4): 290-292. 56. Kwok, S. and Higuchi, R. (1989). 'Avoiding false positives with PCR.' Nature 339(6221): 237-238. 57. Lai, C. C., Sheng, W. H., Wang, J. T., et al. (2013). 'Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.' BMC Infect. Dis. 13: 66. 58. Leclercq, R., Derlot, E., Duval, J., et al. (1988). 'Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.' N. Engl. J. Med. 319(3): 157-161. 59. Leone, S., Noviello, S. and Esposito, S. (2016). 'Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.' Infection 44(3): 273-281. 60. Levesque, L. E., Hanley, J. A., Kezouh, A., et al. (2010). 'Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.' BMJ 340: b5087. 61. Liberati, A., Altman, D. G., Tetzlaff, J., et al. (2009). 'The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.' BMJ 339: b2700. 62. Linden, P. K. (2007). 'Optimizing therapy for vancomycin-resistant enterococci (VRE).' Semin. Respir. Crit. Care Med. 28(6): 632-645. 63. Liu, X., Shen, Y., Wang, H., et al. (2016). 'Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study.' Mediators Inflamm. 2016: 8191254. 64. Lodise, T. P., McKinnon, P. S., Tam, V. H., et al. (2002). 'Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center.' Clin. Infect. Dis. 34(7): 922-929. 65. Longley, N., Muzoora, C., Taseera, K., et al. (2008). 'Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.' Clin. Infect. Dis. 47(12): 1556-1561. 66. Lu, C. L., Chuang, Y. C., Chang, H. C., et al. (2012). 'Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis.' J. Antimicrob. Chemother. 67(9): 2243-2249. 67. Marion, C., Kennedy, L. and High, K. (2008). Daptomycin or linezolid in the treatment of vancomycin-resistant enterococcal bacteremia in neutropenic cancer patients. 46th Annu. Meet. Infect. Dis. Soc. Am. 68. Mascio, C. T., Alder, J. D. and Silverman, J. A. (2007). 'Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.' Antimicrob. Agents Chemother. 51(12): 4255-4260. 69. Mave, V., Garcia-Diaz, J., Islam, T., et al. (2009). 'Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?' J. Antimicrob. Chemother. 64(1): 175-180. 70. McKinnell, J. A. and Arias, C. A. (2015). 'Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience.' Clin. Infect. Dis. 61(6): 879-882. 71. McKinnell, J. A., Patel, M., Shirley, R. M., et al. (2011). 'Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.' Epidemiol. Infect. 139(9): 1342-1350. 72. Moellering, R. C. (2003). 'Linezolid: the first oxazolidinone antimicrobial.' Ann. Intern. Med. 138(2): 135-142. 73. Munita, J. M., Panesso, D., Diaz, L., et al. (2012). 'Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.' Antimicrob. Agents Chemother. 56(8): 4354-4359. 74. Murray, B. E. (2000). 'Vancomycin-resistant enterococcal infections.' N Engl J Med 342(10): 710-721. 75. Naranjo, C. A., Busto, U., Sellers, E. M., et al. (1981). 'A method for estimating the probability of adverse drug reactions.' Clin. Pharmacol. Ther. 30(2): 239-245. 76. Ng, J. K., Schulz, L. T., Rose, W. E., et al. (2014). 'Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.' Antimicrob. Agents Chemother. 58(1): 88-93. 77. Nigo, M., Munita, J. M., Arias, C. A., et al. (2014). 'What's New in the Treatment of Enterococcal Endocarditis?' Curr. Infect. Dis. Rep. 16(10): 431. 78. O'Grady, N. P., Alexander, M., Burns, L. A., et al. (2011). 'Guidelines for the prevention of intravascular catheter-related infections.' Clin. Infect. Dis. 52(9): e162-193. 79. Oleson, F. B., Jr., Berman, C. L., Kirkpatrick, J. B., et al. (2000). 'Once-daily dosing in dogs optimizes daptomycin safety.' Antimicrob. Agents Chemother. 44(11): 2948-2953. 80. Ovstebo, R., Brandtzaeg, P., Brusletto, B., et al. (2004). 'Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease.' J. Clin. Microbiol. 42(7): 2980-2987. 81. Pankey, G. A. and Sabath, L. D. (2004). 'Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.' Clin. Infect. Dis. 38(6): 864-870. 82. Peters, R. P., van Agtmael, M. A., Danner, S. A., et al. (2004). 'New developments in the diagnosis of bloodstream infections.' Lancet Infect. Dis. 4(12): 751-760. 83. Piszczek, J., Hutchinson, J. and Partlow, E. (2015). 'Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis.' J. Antimicrob. Chemother. 70(2): 623-624. 84. Poutsiaka, D. D., Skiffington, S., Miller, K. B., et al. (2007). 'Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.' J. Infect. 54(6): 567-571. 85. Prematunge, C., MacDougall, C., Johnstone, J., et al. (2016). 'VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis.' Infect. Control Hosp. Epidemiol. 37(1): 26-35. 86. Rosenbaum, P. R. and Rubin, D. B. (1983). 'The Central Role of the Propensity Score in Observational Studies for Causal Effects.' Biometrika 70(1): 41-55. 87. Rosmarakis, E. S., Soteriades, E. S., Vergidis, P. I., et al. (2005). 'From conference abstract to full paper: differences between data presented in conferences and journals.' FASEB J. 19(7): 673-680. 88. Rubinstein, E., Isturiz, R., Standiford, H. C., et al. (2003). 'Worldwide assessment of linezolid's clinical safety and tolerability: Comparator-controlled phase III studies.' Antimicrob. Agents Chemother. 47(6): 1824-1831. 89. Rybak, M. J., Hershberger, E., Moldovan, T., et al. (2000). 'In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.' Antimicrob. Agents Chemother. 44(4): 1062-1066. 90. Safdar, N., Andes, D. and Craig, W. A. (2004). 'In vivo pharmacodynamic activity of daptomycin.' Antimicrob. Agents Chemother. 48(1): 63-68. 91. Sakoulas, G., Bayer, A. S., Pogliano, J., et al. (2012). 'Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.' Antimicrob. Agents Chemother. 56(2): 838-844. 92. Sakoulas, G., Nonejuie, P., Nizet, V., et al. (2013). 'Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline.' Antimicrob. Agents Chemother. 57(8): 4042-4045. 93. Sakoulas, G., Rose, W., Nonejuie, P., et al. (2014). 'Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.' Antimicrob. Agents Chemother. 58(3): 1494-1500. 94. Semple, J. W., Italiano, J. E., Jr. and Freedman, J. (2011). 'Platelets and the immune continuum.' Nat. Rev. Immunol. 11(4): 264-274. 95. Shukla, B. S., Gauthier, T. P., Correa, R., et al. (2013). 'Treatment considerations in vancomycin-resistant enterococcal bacteremia: Daptomycin or linezolid? A review.' International Journal of Clinical Pharmacy 35(5): 697-703. 96. Shukla, B. S., Shelburne, S., Reyes, K., et al. (2016). 'Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?' Clin. Infect. Dis. 62(12): 1514-1520. 97. Sierra-Hoffman, M., Iznaola, O., Goodwin, M., et al. (2012). 'Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis.' Antimicrob. Agents Chemother. 56(11): 6064. 98. Smith, J. R., Barber, K. E., Raut, A., et al. (2015). 'beta-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.' J. Antimicrob. Chemother. 70(6): 1738-1743. 99. Stafford, K. A., Boutin, M., Evans, S. R., et al. (2014). 'Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies.' Clin. Infect. Dis. 59(8): 1142-1147. 100. Suppli, M., Aabenhus, R., Harboe, Z. B., et al. (2011). 'Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy.' Clin. Microbiol. Infect. 17(7): 1078-1083. 101. Tally, F. P. and DeBruin, M. F. (2000). 'Development of daptomycin for gram-positive infections.' J. Antimicrob. Chemother. 46(4): 523-526. 102. Twilla, J. D., Finch, C. K., Usery, J. B., et al. (2012). 'Vancomycin-resistant Enterococcus bacteremia: An evaluation of treatment with linezolid or daptomycin.' J. Hosp. Med. 7(3): 243-248. 103. Uttley, A. H., Collins, C. H., Naidoo, J., et al. (1988). 'Vancomycin-resistant enterococci.' Lancet 1(8575-6): 57-58. 104. van Haeften, R., Palladino, S., Kay, I., et al. (2003). 'A quantitative LightCycler PCR to detect Streptococcus pneumoniae in blood and CSF.' Diagn. Microbiol. Infect. Dis. 47(2): 407-414. 105. Vergis, E. N., Hayden, M. K., Chow, J. W., et al. (2001). 'Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study.' Ann. Intern. Med. 135(7): 484-492. 106. Wang, J. L. and Hsueh, P. R. (2009). 'Therapeutic options for infections due to vancomycin-resistant enterococci.' Expert Opin. Pharmacother. 10(5): 785-796. 107. Wei, X. B., Liu, Y. H., He, P. C., et al. (2017). 'The impact of admission neutrophil-to-platelet ratio on in-hospital and long-term mortality in patients with infective endocarditis.' Clin. Chem. Lab. Med. 55(6): 899-906. 108. Weinstock, D. M., Conlon, M., Iovino, C., et al. (2007). 'Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant.' Biol. Blood Marrow Transplant. 13(5): 615-621. 109. Werth, B. J., Barber, K. E., Tran, K. N., et al. (2015). 'Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.' J. Antimicrob. Chemother. 70(2): 489-493. 110. Whang, D. W., Miller, L. G., Partain, N. M., et al. (2013). 'Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.' Antimicrob. Agents Chemother. 57(10): 5013-5018. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69850 | - |
dc.description.abstract | 利奈唑胺linezolid是目前唯一被核可,可治療萬古黴素抗藥性腸球菌vancomycin-resistant enterococci (VRE)的抗生素,不過利奈唑胺的缺點是它屬於抑菌型抗生素。達托黴素daptomycin對於萬古黴素抗藥性腸球菌有很好的殺菌效果,但是目前尚未被核可用於萬古黴素抗藥性腸球菌的治療。我們的假說是達托黴素能做為萬古黴素抗藥性腸球菌菌血症的有效治療抗生素,而達托黴素的治療效果會受到達托黴素劑量及合併乙內醯胺類抗生素的影響。首先,我們先進行系統性回顧及統合分析,以了解達托黴素用於治療萬古黴素抗藥性腸球菌菌血症的現狀。其次,我們在2010-2015年間進行了一個前瞻的觀察性世代研究,進一步了解病患使用達托黴素治療萬古黴素抗藥性腸球菌菌血症的預後。
我們利用PubMed、EMBASE及Cochrane Library搜尋在2014年1月1日前發表,有關萬古黴素抗藥性腸球菌菌血症治療的研究。經篩選,共有13個研究符合篩選條件,其中有523位病患接受達托黴素及656位病患接受利奈唑胺治療。相較於使用利奈唑胺的病患,使用達托黴素的病患有較高的死亡勝算比(odds ratio [OR], 1.43; 95%信賴區間confidence interval [CI], 1.09–1.86; P=.009)。在八個有報告調整勝算比adjusted OR (aOR)的研究做次群組分析,結果也顯示使用達托黴素的病患有較高的死亡勝算比(OR, 1.59; 95% CI, 1.02–2.50; P=.04)。 我們收集了112位使用達托黴素治療萬古黴素抗藥性腸球菌菌血症,且有臨床預後可以評估的病患。多變數迴歸顯示達托黴素劑量≥9 mg/kg相較於達托黴素劑量<7 mg/kg (aOR, 10.57; 95% CI, 2.25–49.62; P=.003)及達托黴素劑量7–9 mg/kg (aOR, 5.01; 95% CI, 1.14–21.98; P=.03)有顯著較佳的存活。我們收集了212位使用達托黴素(n=141)或利奈唑胺(n=71)治療萬古黴素抗藥性腸球菌菌血症的病患。我們發現使用利奈唑胺(aOR, 0.36; 95% CI, 0.17–0.79; P=.01)及使用高劑量達托黴素(≥9 mg/kg) (aOR, 0.26; 95% CI, 0.09–0.74; P=.01) 相較於低劑量達托黴素(6–9 mg/kg)有顯著較低的死亡率。但是使用利奈唑胺相較於使用高劑量達托黴素並沒有死亡率上的優勢(aOR, 1.40; 95% CI, 0.45–4.37; P=.57)。我們收集了114位使用達托黴素治療萬古黴素抗藥性腸球菌菌血症來評估合併乙內醯胺類抗生素使用對預後的影響。有87位病患(76.3%)有接受達托黴素合併乙內醯胺類抗生素使用。相較於單獨使用低劑量達托黴素(調整危險比adjusted hazard ratio [aHR], 5.16;95% CI, 1.34–19.89; P=.02),使用低劑量達托黴素合併乙內醯胺類抗生素(aHR, 5.39; 95% CI, 1.62–17.93;P=.006),及單獨使用高劑量達托黴素(aHR, 19.01; 95% CI, 2.96–121.95; P=.002),高劑量達托黴素合併乙內醯胺類抗生素有最佳的病患存活率。我們收集了108位使用達托黴素(n=78)或利奈唑胺(n=30)治療萬古黴素抗藥性腸球菌菌血症的病患,用以做為血液中菌量的追蹤。我們使用即時定量聚合酶鏈鎖反應定量血中菌量。我們發現較慢的血中菌量清除速度(log10 copies/mL/day)和較高的死亡率有顯著的相關(aOR, 3.21; 95% CI, 1.03–10.02; P=.045)。相較於使用低劑量達托黴素,利奈唑胺(–0.04 vs. –0.41; P<.001),及高劑量達托黴素(–0.04 vs. –0.56; P=.043)有顯著較佳的血中菌量清除速度。 在目前的統合分析中,我們發現達托黴素相較於利奈唑胺有較高的死亡率。因為納入統合分析的研究都是小規模的回溯性研究,而且達托黴素的使用劑量可能不足,所以統合分析的結果要小心的解讀。在萬古黴素抗藥性腸球菌菌血症的臨床觀察中我們發現高劑量達托黴素(≥9 mg/kg),顯然的在治療萬古黴素抗藥性腸球菌菌血症有較低的死亡率。雖然低劑量達托黴素相較於利奈唑胺有較高的死亡率,但利奈唑胺相較於高劑量達托黴素並沒有較佳的存活率。高劑量達托黴素合併乙內醯胺類抗生素可以改善病患存活率。而利奈唑胺及高劑量達托黴素相較於低劑量達托黴素有較佳的血中菌量清除速度。因此我們的結論是可以考慮使用高劑量達托黴素來治療萬古黴素抗藥性腸球菌菌血症,並考慮合併乙內醯胺類抗生素使用。 | zh_TW |
dc.description.abstract | Linezolid, which has bacteriostatic activity, is approved for the treatment of vancomycin-resistant enterococci (VRE) infections. Daptomycin exerts bactericidal activity against VRE, but is not approved for the treatment of VRE bloodstream infection (BSI). We hypothesize that daptomycin can be used as an effective antimicrobial agent for the treatment of VRE-BSI, and that daptomycin dose and beta-lactam combination therapy may affect the outcome of daptomycin treated VRE-BSI. We therefore performed a systematic review and meta-analysis followed by a prospective observational cohort study in 2010–2015.
PubMed, EMBASE, and the Cochrane Library were searched for studies on the treatment of VRE-BSI published prior to January 1, 2014. Thirteen studies (532 patients receiving daptomycin, 656 patients receiving linezolid) met the selection criteria. Mortality was higher in patients receiving daptomycin treatment (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.09–1.86; P=.009). Subgroup analysis of eight studies that reported adjusted odds ratios (aORs) indicated that daptomycin treatment was associated with a higher mortality rate (OR, 1.59; 95% CI, 1.02–2.50; P=.04). We included 112 patients treated with daptomycin for VRE-BSI, with evaluable clinical outcomes. The best outcomes were associated with a daptomycin dose of ≥9 mg/kg compared with doses of <7 mg/kg (aOR, 10.57; 95% CI, 2.25–49.62; P=.003) and 7–9 mg/kg (aOR, 5.01; 95% CI, 1.14–21.98; P=.03). We included 212 patients treated with daptomycin or linezolid for VRE-BSI (daptomycin, n=141; linezolid, n=71). Logistic regression showed that linezolid (aOR, 0.36; 95% CI, 0.17–0.79; P=.01) and high-dose daptomycin (≥9 mg/kg) (aOR, 0.26; 95% CI, 0.09–0.74; P=.01) independently predicted lower mortality compared with low-dose daptomycin (6–9 mg/kg). Linezolid was not superior to high-dose daptomycin in terms of mortality (aOR, 1.40; 95% CI, 0.45–4.37; P=.57). We included 114 patients who received daptomycin for VRE-BSI to evaluate the effect of beta-lactam antibiotic (BLA) combinations. Of these, 87 (76.3%) received daptomycin+BLA. Patients receiving high-dose daptomycin+BLA independently had better survival than those receiving low-dose daptomycin alone (adjusted hazard ratio [aHR]=5.16), low-dose daptomycin+BLA (aHR=5.39), and high-dose daptomycin alone (aHR=19.01) (P<.05 for all comparisons). We included 108 patients with VRE-BSI for real-time quantitative polymerase chain reaction analysis of in vivo bacterial load. Slower early bacterial clearance (aOR, 3.21; 95% CI, 1.03–10.02; P=.045) independently predicted mortality. Compared with the bacterial clearance of low-dose daptomycin, linezolid and high-dose daptomycin produced rapid bacterial clearance (log10 copies/mL/day; −0.04 vs. −0.41; P<.001, and −0.04 vs. −0.56; P = .043; respectively). The current meta-analysis shows that linezolid treatment for VRE-BSI was associated with a lower mortality than daptomycin treatment. This result should be interpreted cautiously, however, because of limitations inherent to retrospective studies of small sample size and the high heterogeneity among the studies. High-dose daptomycin (≥9 mg/kg) was associated with lower mortality in patients with VRE-BSI. Despite having a lower mortality compared with low-dose daptomycin, linezolid conferred no survival benefit compared with high-dose daptomycin. High-dose daptomycin and BLA combination therapy might improve survival. High-dose-daptomycin and linezolid use were associated with rapid bacterial clearance compared with low-dose daptomycin. Our results thus suggest that high-dose daptomycin and BLA combination therapy might be an appropriate regimen for the treatment of VRE-BSI. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:30:48Z (GMT). No. of bitstreams: 1 ntu-107-D00421011-1.pdf: 4328250 bytes, checksum: aeecc08dc0a9feda4c332a5f3ddf904e (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書 IV
誌謝 V 摘要 VI ABSTRACT VIII INDEX OF TABLES XI INDEX OF FIGURES XII CHAPTER 1. INTRODUCTION 1 1.1 Vancomycin-Resistant Enterococci 1 1.2 Systematic Review and Meta-Analysis 2 1.3 Effect of Daptomycin Dose 3 1.4 Daptomycin versus Linezolid: Implications of Daptomycin Dose 5 1.5 Combination Therapy of Daptomycin and a Beta-Lactam Antibiotic 7 1.6 Monitoring the Bacterial Load in vivo 9 1.7 Hypothesis 10 1.8 Specific Aims 11 CHAPTER 2. MATERIALS AND METHODS 13 2.1 Systematic Review and Meta-Analysis 13 2.1.1 Literature search 13 2.1.2 Study selection 13 2.1.3 Data extraction, definitions, and outcomes 14 2.1.4 Statistical analysis 15 2.2 Clinical Studies 15 2.2.1 Hospital setting and patients 15 2.2.2 Microbiological studies and antimicrobial susceptibility testing 16 2.2.3 Blood sample collection and qPCR assays 17 2.2.4 Clinical data collection and definitions 19 2.2.5 Inclusion and exclusion criteria and outcome definitions 20 2.2.6 Statistical analysis 23 CHAPTER 3. RESULTS 27 3.1 Systematic Reviews and Meta-Analysis 27 3.1.1 Characteristics of included studies 27 3.1.2 Meta-analysis results 29 3.2 Effect of Daptomycin Dose In the Daptomycin Cohort 32 3.2.1 Clinical characteristics 32 3.2.2 Generalized additive model analysis 34 3.2.3 Association between daptomycin dose, MIC, and mortality 34 3.2.4 Selection of the cut-off dose for daptomycin 35 3.2.5 Sensitivity analysis 36 3.2.6 Daptomycin MIC determined by Etest 37 3.2.7 Association between daptomycin dose, Etest-determined MIC, and patient outcomes 37 3.2.8 Microbiological outcome 38 3.2.9 Elevation of CK 39 3.3 Daptomycin versus Linezolid: Implications of Daptomycin Dose Among the Daptomycin-versus-Linezolid Cohort 39 3.3.1 Clinical characteristics 39 3.3.2 Mortality analysis 40 3.3.3 Association between daptomycin dose and mortality 41 3.3.4 Sensitivity analysis 42 3.4 Combination of Daptomycin and a BLA in the Beta-lactam-Evaluation Cohort 44 3.4.1 Clinical characteristics 44 3.4.2 Mortality analysis 45 3.4.3 Influence of daptomycin MIC on the effect of daptomycin+BLA 46 3.4.4 Influence of daptomycin dose on the effect of daptomycin+BLA 47 3.4.5 Sensitivity analysis 48 3.5 In Vivo Bacterial Load Monitoring In the qPCR Cohort 49 3.5.1 Clinical characteristics 50 3.5.2 Real-time qPCR monitoring of VRE-BSI 50 3.5.3 Factors associated with mortality 51 3.5.4 Sensitivity analysis 52 3.5.5 Factors associated with bacterial load changes 52 CHAPTER 4. DISCUSSION 54 4.1 Systematic Reviews and Meta-Analysis 54 4.2 Effect of Daptomycin Dose on the Outcome of Vancomycin-resistant, Daptomycin-susceptible E. faecium Bacteremia 56 4.3 Daptomycin versus Linezolid for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia: Implications of Daptomycin Dose 58 4.4 Does the Combination of Daptomycin and a BLA Improve the Outcome of Patients with VRE-BSI? 64 4.5 Monitoring the Bacterial Load in Patients with Vancomycin-Resistant E. faecium Bloodstream Infection 68 CHAPTER 5. PERSPECTIVES AND CONCLUSIONS 71 5.1 Systematic Reviews and Meta-Analysis 71 5.2 Effect of Daptomycin Dose on the Outcome of Vancomycin-resistant, Daptomycin-susceptible E. faecium Bacteremia 75 5.3 Daptomycin versus Linezolid for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia: Implications of Daptomycin Dose 76 5.4 Does the Combination of Daptomycin and a BLA Improve the Outcome of Patients with VRE-BSI? 77 5.5 Bacterial Load Monitoring in Patients with VRE-BSI 78 5.6 Conclusions 80 CHAPTER 6. REFERENCES 83 TABLES 101 FIGURES 133 ABBREVIATIONS 156 APPENDIX 157 修業期間所發表之相關論文 157 修業期間所發表之其它論文 158 第一或通訊作者 158 | |
dc.language.iso | en | |
dc.title | 達托黴素於萬古黴素抗藥性腸球菌菌血症的治療應用 | zh_TW |
dc.title | Daptomycin for the treatment of vancomycin-resistant enterococcal bloodstream infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 莊銀清,張峰義,王振泰,陳祈玲 | |
dc.subject.keyword | 萬古黴素抗藥性腸球菌,菌血症,達托黴素, | zh_TW |
dc.subject.keyword | vancomycin-resistant enterococci,bloodstream infection,daptomycin, | en |
dc.relation.page | 159 | |
dc.identifier.doi | 10.6342/NTU201800628 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-02-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 4.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。